SummaryThe effect of several tissue thromboplastins on the abnormal factor X (factor X Friuli) has been investigated.The prothrombin time varied between 33.6 and 69 sec. The prothrombin time percentile values (saline dilution curve and Quick’s formula for citrated plasma) varied between 6.6 and 22% and between 10.9 and 32.8%, respectively. The prothrombin time patient/normal ratio varied between 2.24 and 4.43.The factor X level varied between 3.5 and 20% of normal.Significant correlations were found to exist between the percentile factor X level and the prothrombin time in seconds, the percentile prothrombin time values and the prothrombin time patient/normal ratio. Thromboplastins of human origin yielded the lowest factor X values namely 5% thereby appearing to be practically “inert” with regard to the abnormal factor X. Thromboplastins obtained from rabbit lung on the contrary yielded the highest values, namely 15.3%. Thromboplastins obtained from simian or rabbit brain gave values intermediate between these two extremes.
ABSTRACT
Comparison of the dose-response curves for LH of ovine origin (NIH-LH-S8) and of human origin (IRP-HMG-2) using the OAAD test showed a small, though statistically significant difference, the dose-response curve for LH of human origin being a little flatter. Two standard curves for ovine LH obtained with 14 months' interval, were parallel but at different levels of ovarian ascorbic acid. When the mean ascorbic acid depletions were calculated as percentages of the control levels, the two curves for NIH-LH-S8 were identical. The use of standards of human origin in the OAAD test for LH activity of human preparations is recommended.
Nosocomial infections in the elderly, often suffering from many ailments, patients in homes for the disabled and the old are among the problematic diseases that specialized nursing staff and doctors have to deal with more often in such institutions. Review work from the USA introduces relevant information about infectious risks, as well as possible preventive and therapeutic measures.